

47. (Amended) A method of treatment for a disease, wherein the disease is selected from the group consisting of atherosclerosis, cardiovascular disease, diabetes, retinopathy, cataract formation, Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, 21 trisomy, and hypertension, wherein the method comprises administering a replication defective, recombinant adenovirus comprising a DNA sequence which encodes an intracellular CuZn superoxide dismutase-1 (SOD-1), wherein the DNA sequence is under the control of a signal enabling expression in a target cell, to a patient suffering from such a disease.

62. (Amended) The method of treatment according to claim 61, wherein the cDNA sequence encodes human intracellular CuZn superoxide dismutase-1 (hSOD-1).

68. (Amended) The method of treatment according to claim 62, wherein the cDNA sequence encodes human intracellular CuZn superoxide dismutase-1 (hSOD1) under the control of an RSV-LTR promoter.

81. (Amended) The method of treatment of any one of claims 69-75, wherein the superoxide dismutase is human intracellular CuZn superoxide dismutase-1 (hSOD1).

In accordance with the requirements of 37 C.F.R. § 1.121, the attached Appendix shows the changes to the specification and claims that have been made by the proposed amendment.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com